Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 1,514 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $8.24, for a total transaction of $12,475.36. Following the completion of the transaction, the insider now directly owns 8,659 shares of the company's stock, valued at approximately $71,350.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Verve Therapeutics Price Performance
Shares of Verve Therapeutics stock opened at $8.71 on Thursday. The firm has a fifty day moving average price of $13.17 and a 200 day moving average price of $12.76. Verve Therapeutics, Inc. has a 1 year low of $7.36 and a 1 year high of $21.42. The stock has a market cap of $728.32 million, a PE ratio of -2.79 and a beta of 1.70.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.14. Verve Therapeutics had a negative net margin of 1,701.70% and a negative return on equity of 39.33%. The company had revenue of $5.14 million during the quarter, compared to analysts' expectations of $3.95 million. As a group, equities analysts expect that Verve Therapeutics, Inc. will post -3.04 EPS for the current year.
Institutional Inflows and Outflows
The #1 Biotech Stock to Have on Your Radar in 2024…
From Huge Alerts | Ad
Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!
Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now!
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VERV. PNC Financial Services Group Inc. purchased a new position in Verve Therapeutics in the fourth quarter valued at $29,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Verve Therapeutics in the fourth quarter valued at about $30,000. Quest Partners LLC acquired a new stake in shares of Verve Therapeutics in the fourth quarter valued at about $34,000. Amundi acquired a new stake in shares of Verve Therapeutics in the fourth quarter valued at about $45,000. Finally, Penserra Capital Management LLC acquired a new stake in shares of Verve Therapeutics in the first quarter valued at about $46,000. Hedge funds and other institutional investors own 97.11% of the company's stock.
Wall Street Analyst Weigh In
VERV has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $35.00 price target on shares of Verve Therapeutics in a report on Wednesday, February 28th. Stifel Nicolaus reduced their target price on shares of Verve Therapeutics from $56.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Verve Therapeutics has an average rating of "Moderate Buy" and an average target price of $35.33.
Get Our Latest Stock Report on VERV
Verve Therapeutics Company Profile
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
